I am a
Home I AM A Search Login

Papers of the Week

2020 Jul 08

J Patient Rep Outcomes



A prospective study to validate the functional assessment of cancer therapy (FACT) for epidermal growth factor receptor inhibitor (EGFRI)-induced dermatologic toxicities FACT-EGFRI 18 questionnaire: SWOG S1013.


Wong S-F, Unger JM, Wade JL, Wagner LI, Lacouture ME, Humphries KC, Moseley A, Arnold K, Velasco MR, Floyd JD, Esparaz BT, Barzi A, Lenz H-J, Koczywas M, Dakhil S, Burton GV, Fisch MJ, Henry LN, Hershman DL, Moinpour CM
J Patient Rep Outcomes. 2020 Jul 08; 4(1):54.
PMID: 32642992.


Papulopustular rash is a common class effect of epidermal growth factor receptor inhibitors (EGFRI) that can affect patients' health-related quality of life and cause disruptions to treatment. SWOG S1013 (NCT01416688) is a multi-center study designed to validate the Functional Assessment of Cancer Therapy EGFRI 18 (FACT-EGFRI 18) using 7-items from the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 to assess EGFRI-induced skin-related toxicities and their impact on functional status.